Eagle Pharmaceuticals, INC 8-K filings

Eagle Pharmaceuticals has amended its Rights Agreement to clarify the Board's authority, following its delisting from the Nasdaq.

Eagle Pharmaceuticals has dismissed Ernst & Young as its auditor and appointed BDO, following the need to restate several years of financial statements due to identified material weaknesses in internal controls.

Eagle Pharmaceuticals has announced its intention to delist from the Nasdaq and file a Form 25 with the SEC, completing its move to the OTC Expert Market.

Eagle Pharmaceuticals has appointed Christopher Krawtschuk as its new Chief Financial Officer, effective November 11, 2024, following the company's delisting from the Nasdaq.

Eagle Pharmaceuticals has adopted a limited duration stockholder rights plan to protect against hostile takeovers and ensure all stockholders can realize the long-term value of their investment.

Eagle Pharmaceuticals is facing delisting from Nasdaq due to accounting errors and delays in financial reporting, leading to a credit agreement default and a review of financing alternatives.

Eagle Pharmaceuticals has amended its credit agreement due to reporting defaults and covenant breaches, and has received a delisting notice from Nasdaq for failing to file its quarterly report.

Eagle Pharmaceuticals has received an extension from Nasdaq to maintain its listing, contingent on filing overdue financial reports by specific deadlines.

Eagle Pharmaceuticals has reached a settlement with Curia, resolving all outstanding legal claims and counterclaims, and agreeing to a $26.5 million payment.

Eagle Pharmaceuticals has requested a hearing with Nasdaq to appeal a potential delisting due to delayed financial filings.

Eagle Pharmaceuticals has received a delisting notice from Nasdaq due to the company's failure to file required financial reports.

Eagle Pharmaceuticals has amended its credit agreement, extending the deadline for financial reporting and permanently reducing its revolving credit facility.

Eagle Pharmaceuticals has received a notice from Nasdaq regarding non-compliance with listing rules due to the delayed filing of its annual report, potentially leading to delisting.

Eagle Pharmaceuticals' Chief Financial Officer Brian Cahill has resigned, and Steven Ratoff has been appointed as Interim CFO, effective immediately.

Eagle Pharmaceuticals has amended its credit agreement for the second time, extending deadlines for financial reporting and modifying certain restrictions.

Eagle Pharmaceuticals is implementing a realignment plan that includes a 36% workforce reduction to improve operational efficiencies and realign sales and marketing expenditures.

Eagle Pharmaceuticals has received a 180-day extension from Nasdaq to regain compliance with listing rules after a delay in filing its quarterly report.

Eagle Pharmaceuticals has announced an update on its bendamustine intellectual property portfolio, including the grant of two new patents and the filing of lawsuits against companies for alleged infringement.

Eagle Pharmaceuticals has obtained a limited waiver and amendment to its credit agreement, addressing defaults related to delayed and inaccurate financial statements.